Capsaicin-Loaded Chitosan Nanocapsules for wtCFTR-mRNA Delivery to a Cystic Fibrosis Cell Line by Kolonko, AK et al.
biomedicines
Article
Capsaicin-Loaded Chitosan Nanocapsules for
wtCFTR-mRNA Delivery to a Cystic Fibrosis
Cell Line
A. Katharina Kolonko 1,*, Janes Efing 1, Yadira González-Espinosa 2, Nadine Bangel-Ruland 1,
Willy van Driessche 3, Francisco M. Goycoolea 2 and Wolf-Michael Weber 1
1 Institute of Animal Physiology, University of Muenster, Schlossplatz 8, 48143 Muenster, Germany;
j_efin04@wwu.de (J.E.); n.br@wwu.de (N.B.-R.); wmw@wwu.de (W.-M.W.)
2 School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK;
Y.GonzalezEspinosa@leeds.ac.uk (Y.G.-E.); F.M.Goycoolea@leeds.ac.uk (F.M.G.)
3 EP-Devices, Tervuursesteenweg 154, 3060 Bertem, Belgium; ep.devices@telenet.be
* Correspondence: katharina.kolonko@wwu.de; Tel.: +49-251-8321784
Received: 12 August 2020; Accepted: 18 September 2020; Published: 20 September 2020


Abstract: Cystic fibrosis (CF), a lethal hereditary disease caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene coding for an epithelial chloride channel,
is characterized by an imbalanced homeostasis of ion and water transports in secretory epithelia.
As the disease is single-gene based, transcript therapy using therapeutic mRNA is a promising concept
of treatment in order to correct many aspects of the fatal pathology on a cellular level. Hence,
we developed chitosan nanocapsules surface-loaded with wtCFTR-mRNA to restore CFTR function.
Furthermore, we loaded the nanocapsules with capsaicin, aiming to enhance the overall efficiency
of transcript therapy by reducing sodium hyperabsorption by the epithelial sodium channel (ENaC).
Dynamic light scattering with non-invasive back scattering (DLS-NIBS) revealed nanocapsules with an
average hydrodynamic diameter of ~200 nm and a Zeta potential of ~+60 mV. The results of DLS-NIBS
measurements were confirmed by asymmetric flow field-flow fractionation (AF4) with multidetection,
while transmission electron microscopy (TEM) images confirmed the spherical morphology and size
range. After stability measurements showed that the nanocapsules were highly stable in cell culture
transfection medium, and cytotoxicity was ruled out, transfection experiments were performed with
the CF cell line CFBE41o-. Finally, transepithelial measurements with a new state-of-the-art Ussing
chamber confirmed successfully restored CFTR function in transfected cells. This study demonstrates
that CS nanocapsules as a natural and non-toxic delivery system for mRNA to target cells could
effectively replace risky vectors for gene delivery. The nanocapsules are not only suitable as a transcript
therapy for treatment of CF, but open aspiring possibilities for safe gene delivery in general.
Keywords: CFTR; ENaC; chitosan; mRNA therapy; nanocapsules; cystic fibrosis; capsaicin;
transcript therapy
1. Introduction
Messenger RNA (mRNA) is a single-stranded nucleic acid, which transfers genetic information to
the ribosome, where protein synthesis takes place. The use of mRNA for therapeutic purposes, such as
the so-called transcript therapy, has been tested since the early 1990s and has undergone tremendous
developments since then [1]. In fact, mRNA displays many advantages for gene delivery compared
to DNA. For example, there is no need for nuclear localization facilitating the delivery to the target,
namely the cytosol, and the risk of insertional mutagenesis, followed by oncogenic effects, is being
avoided. Furthermore, mRNA is smaller than DNA, providing easier transport into the cell; it also
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exhibits reduced immunogenicity and is efficient at any point of the cell cycle [2]. Currently, three
clinical trials are testing the efficiency of mRNA-based therapies targeting different proteins, including
the cystic fibrosis transmembrane conductance regulator (CFTR) via lipid nanoparticle inhalation for
the treatment of cystic fibrosis (CF) [3].
CF, being the most common lethal genetic disorder in Caucasians, is caused by mutations in
the CFTR gene encoding for a cAMP-dependent chloride and bicarbonate channel mainly expressed
in the apical membrane of secretory epithelial cells. The defect chloride secretion through CFTR is
associated with sodium hyperabsorption via the amiloride-sensitive epithelial sodium channel (ENaC).
The classical clinical picture caused by the imbalanced homeostasis of ion and water transport is
mainly characterized by fat maldigestion due to pancreatic insufficiency [4,5] and chronic obstructive
lung disease with bacterial colonization by microorganisms such as Pseudomonas aeruginosa and
Staphylococcus aureus [6]. Thanks to improved treatment and early diagnosis, the median survival for
patients born in 2000 is expected to be in excess of 50 years [7]. Even though innovative treatment
strategies, such as personalized medicine using CFTR modulators, have improved the quality of life,
as well as the life expectancy of patients significantly [8,9], a causative treatment for CF still needs to
be found in order to treat all patients, regardless of their genotype.
In our group, we have been working with wtCFTR-mRNA to improve chloride secretion
of epithelial cells constantly optimizing delivery methods [10–12]. The most promising delivery
systems of nucleic acids to epithelial cells proved to be self-assembled polyelectrolyte chitosan
(CS)-based nanocomplexes due to their low cytotoxicity and high transfection efficiency [12–14].
CS itself, a family of pseudonatural polysaccharides composed of randomly distributed β-(1-4)-linked
D-glucosamine and N-acetyl-D-glucosamine units, is a promising candidate for non-viral gene
delivery [15]. Because of its positive attributes, such as biocompatibility, mucoadhesiveness, low
cytotoxicity, and low immunogenicity, CS has already been used as a carrier for various drugs in
multiple studies [16–18]. However, our matrix-type nanosystems displayed poor stability in transfection
medium, possibly reducing transfection efficacy. Therefore, we aimed at developing a new delivery
system with improved stability and higher transfection efficiency.
We prepared CS-lecithin oil-core nanocapsules with the solvent displacement technique according
to the principle of spontaneous emulsification [19,20]. Briefly, these nanocapsules consist of an oil-core
lined with lecithin. The hydrophilic head groups of the phospholipidic surfactant face to the outside,
enabling the phospholipids to interact with oppositely charged CS via electrostatic binding forming a
core-shell colloidal nanocapsule. For transfection purposes, we loaded wtCFTR-mRNA to the surface of
the nanosystems, using a layer-by-layer electrostatic assembly principle, thus forming a polyelectrolyte
complex shell. Furthermore, we loaded capsaicin in the oil-core of the nanocapsules with a view to
potentially increase transfection efficiency, as the compound has been found to reversibly open tight
junctions [21,22] and to have mucus thinning properties [23,24], which can be advantageous in the
CF lung.
Capsaicin, the main pungent alkaloid found in members of the Capsicum family, e.g., the chili pepper,
is the agonist to the transient receptor potential vanilloid 1 (TRPV1), a ligand-gated, calcium-permeable
cation channel mainly expressed in cells of the nervous system [25,26]. Capsaicin has been known
for its wide range of therapeutic properties since ancient times [27]. The current main therapeutic
application is as an analgesic in topical creams and dermal patches against neuropathic pain [28,29].
However, many other therapeutic benefits have been described [30]. Recent studies have documented
that capsaicin has a direct effect on urinary sodium excretion by inhibiting ENaC function and thereby
affecting renal sodium reabsorption [31]. We have, therefore, hypothesized that bundling capsaicin in a
nanocapsules formulation, including electrostatically bound CS and wtCFTR-mRNA, would not only
lead to an increased transfection efficiency but, as a secondary effect, also to a decreased ENaC activity;
thus, this approach may result in a double-tracked strategy to target CFTR and ENaC simultaneously.
In this study, we aimed at developing stable CS nanocapsules incorporating capsaicin to increase
transfection efficiency of wtCFTR-mRNA in a CF cell line. Our results indicate successfully restored
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CFTR function after treatment with the CS nanocapsules, demonstrating the aspiring possibilities of a
non-viral transcript therapy as a treatment for CF.
2. Experimental Section
2.1. mRNA Synthesis
For synthesis of wtCFTR-mRNA via in vitro transcription (IVT), the construct pSTI-A120/hCFTR-
cDNA provided by C. Rudolph (Ludwig Maximilian University of Munich, Munich, Germany) was used.
The construct pALTER-A120/h∆F508-CFTR provided by K. Kunzelmann (University of Regensburg,
Regensburg, Germany) was used for synthesis of ∆F508-CFTR-mRNA. The mRNA synthesis was
performed as described previously [10]. Briefly, the linearized plasmid was precipitated with
ethanol/sodium acetate after extraction with phenol/chloroform. The IVT reaction was performed with
the mMESSAGE mMACHINE™ T7 Transcription Kit (Invitrogen, Carlsbad, CA, USA). For purification
of the reaction, the RNeasy® Plus Mini Kit (Qiagen, Hilden, Germany) was used. Finally, the mRNA
was precipitated with ethanol/ammonium acetate and dissolved in RNase-free water. The concentration
of the product was determined by absorbance measurement at 260 nm, using a microvolume
spectrophotometer (NanoDrop 1000, Peqlab Biotechnologie GmbH, Erlangen, Germany), while
the integrity and size distribution was determined by agarose-formaldehyde gel electrophoresis.
The mRNA was stored at −20 ◦C, in nuclease-free water.
2.2. Chitosan-Lecithin Oil-Core Nanocapsules
The CS was purchased from HMC+ GmbH (Halle/Saale, Germany) as an ultrapure
biomedical-grade sample (Heppe 70/5; Batch-No. 212-170614-01; DA = 17%; Mw = 29.3%). It was
dissolved in water with 5% stoichiometric excess of 5 M HCl.
The nanocapsules (NC) were prepared as described previously, with slight modifications [22].
Briefly, 400 µL ethanolic lecithin solution (100 mg/mL) and 530 µL capsaicin stock solution (24 mg/mL
in ethanol) were mixed and supplemented with 125 µL Miglyol® 812 N and 9.5 mL ethanol.
Under constant stirring, this organic solution was then poured into 20 mL aqueous CS solution
(0.5 mg/mL). Concentration of the milky mixture was performed at 40 ◦C, using a rotavapor (Büchi
R-210, Büchi Labortechnik GmbH, Essen, Germany). During the process, the pressure was slowly
decreased to 0 mbar, until 3.5–4.0 mL remained. To yield a final CS concentration of 2.5 mg/mL and a
final capsaicin concentration of 10 mM, the volume was topped up to 4.0 mL with water. Unloaded
nanocapsules were prepared similarly by using ethanol instead of the capsaicin solution.
The nanocapsules were loaded with mRNA by carefully mixing 15 µL of nanocapsules
with different volumes of wtCFTR-mRNA (0.053 µg/µL), to reach varying charge ratios (Table 1).
The nanocapsules were incubated for 30 min, at room temperature (RT), to allow complexation of the
mRNA and the CS.
Table 1. Composition of the chitosan (CS) nanocapsules surface-loaded with wtCFTR-mRNA, at varying
positive/negative (P/N) charge ratios.
Charge Ratio wtCFTR-mRNA Chitosan
P/N 1 (nmol) 2 (µg/µL) (nmol) 3 (µg/µL)
5 33.8 0.053 185.1 2.5
10 17.8 0.053 185.1 2.5
50 3.7 0.053 185.1 2.5
75 2.5 0.053 185.1 2.5
100 1.9 0.053 185.1 2.5
1 Charge ratio (P/N): molar ratio of equivalent charges of NH3+/PO4−, 2 wtCFTR-mRNA (nmol): equivalent
concentration of PO4− from the wtCFTR-mRNA, 3 Chitosan (nmol): equivalent concentration of NH3+ from CS.
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2.3. Determination of Size Distribution and Zeta Potential
Dynamic light scattering with non-invasive back scattering (DLS-NIBS) with a measurement
angle of 173◦ was performed to measure the size distribution of the nanocapsules [32]. Their zeta
potential (ζ) was determined by applying the Henry equation, using the Smolouchowski approximation
after exerting laser Doppler microelectrophoresis and phase analysis light scattering (M3-PALS) [33].
For measurements, the nanocapsules were diluted in water (1:67) and filled into a folded capillary zeta
potential cell (Model DTS1070; Malvern Panalytical Ltd., Worcestershire, UK). Measurements were
performed at 25 ◦C with a Zetasizer Nano ZS 6300 instrument (Malvern Panalytical Ltd., Worcestershire,
UK). Data were acquired with 4 measurements each, with runs set automatically.
2.4. Stability Measurements
The size distribution of the nanocapsules was measured at different time points by DLS-NIBS,
with a measurement angel of 173◦, in order to determine their stability in transfection medium.
The nanocapsules were prepared at RT and diluted in transfection medium (1:67; Opti-MEM™ (Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with 20 mM HEPES and 270 mM mannitol).
Subsequently, nanocapsules were incubated at 37 ◦C in between measurements. Measurements were
performed after 0, 4, and 24 h, at 37 ◦C, using a low volume disposable cuvette (Sarstedt AG & Co,
Hemer, Germany) with a Zetasizer Nano ZS 6300 instrument (Malvern Panalytical Ltd., Worcestershire,
UK). Data were acquired with 4 measurements each, with runs set automatically.
2.5. Gel Retardation Assay
To test the binding efficiency of nucleic acids to CS, a gel retardation assay was carried out.
For preparation of the samples, 5 µL wtCFTR-mRNA (0.053 µg/µL) was mixed with 5 µL nanocapsules
(blank and loaded) and incubated for 30 min at RT, or were incubated in 20 µL Opti-MEM™, at 37 ◦C,
for 24 h. After addition of 2 × RNA loading dye (Thermo Fisher Scientific, Waltham, MA, USA),
the nanosystems were loaded onto a 1% agarose-formaldehyde gel in RNA running buffer (0.1 M
Mops, 50 mM sodium acetate, 5 mM EDTA; pH 7) and electrophoresed at 128 V for 45 min. Finally,
the nucleic acid bands were visualized in a BioDocAnalyze System (Analytik Jena, Jena, Germany).
2.6. Asymmetric Flow Field-Flow Fractionation
Asymmetric flow field-flow fractionation (AF4) measurements [34] were performed on an AF2000
Multiflow system from Postnova Analytics GmbH (Landsberg am Lech, Germany). The system was
set to be operated in AF4 mode and was coupled with an online 21 angle multi-angle light scattering
detector MALS (PN3621), a refractive index detector RI (PN3150), and a dual wavelength UV detector
(PN3211) set at 280 and 220 nm. A DLS-NIBS detector (Zetasizer Nano ZS, Malvern Panalytical Ltd.,
Worcestershire, UK) was fitted online for determination of the hydrodynamic radius, using a light
path quartz flow cell (ZEN0023) and 173◦ backscattered angle. The AF4 system was equipped with an
analytical asymmetric AF4 cartridge design channel (Postnova Z-AF4-CHA-611, Postnova Analytics
GmbH, Landsberg am Lech, Germany), using a 350 µm spacer. A thermostat (PN4020) set at 30 ◦C for
all experiments controlled the temperature of the channel, and a membrane with a 10 kDa cutoff made
of regenerated cellulose was used (Z-AF4-MEM-612-10KD, Postnova Analytics, Landsberg am Lech,
Germany). In order to minimize the interactions between the positively charged nanocapsules and the
residual negatively charged groups of the membrane, an acetate buffer solution (0.18 M acetic acid,
0.02 M sodium acetate; pH 3.7) was used as a carrier liquid, leading to the surface of the membrane
being charged positively (ζ ~+10 mV). This favors the polymer elution generating repulsive forces
between both the positively charged CS-covered nanocapsules and cellulose membrane [35].
For experiments, the nanocapsules were diluted in the acetate buffer solution (4:1), and for
each run, 2 µL of sample was injected into the system. The elution was carried out by a cross-flow
programmed with a time delay exponential decay. The sample was injected at 0.2 mL/min and then
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focused at a rate of 1.3 mL/min, for 3 min, with the cross-flow set at 1 mL/min. After the focusing
period and a transition period of 0.2 min, the profile of the cross-flow was gradually decreased over one
hour, with a series of consecutive steps. (a) The cross-flow was kept constant at 1 mL/min for 0.2 min.
(b) The cross-flow was decreased at an exponent decay from 0.2 to 0.1 mL/min over 40 min. (c) Finally,
the cross-flow was kept constant at 0.1 mL/min for 20 min. During the entire process, including the
focus step, the detector flow was maintained at 0.5 mL/min. Data collection and analysis were achieved
with NovaFFF software version 2.0.9.9. (Postnova Analytics GmbH, Landsberg am Lech, Germany),
and data were best fitted to random coil model.
2.7. Transmission Electron Microscopy
The ultrastructure of the nanocapsules was investigated by using transmission electron microscopy
(TEM). Equal amounts of samples were mixed with uranyl acetate solution (negative staining, 1% w/v).
Samples (8 µL) were placed onto a copper grid covered with Formvar® film, and the excess of liquid
was removed with the aid of a filter paper. The analyses were performed by using JEM-1400 TEM
(JEOL, Peabody, MA, USA), operated at 100 kV, and captured on AMT 1K CCD, using the software
AMTV602 (Advanced Microscopy Techniques, Woburn, MA, USA).
2.8. Cell Culture
Dr. Dieter Gruenert (Department of Otolaryngology—Head and Neck Surgery, University of
California, San Francisco, CA, USA) provided 16HBE14o- and CFBE41o- cells. Cells were cultivated
in T-75 flasks on 1% fibronectin in Minimal Essential Medium Earle’s supplemented with 10% fetal
calf serum, 2 mM L-glutamine, and 100 U/mL penicillin/streptomycin, at 37 ◦C, with 5% CO2 and 95%
rH. For Ussing chamber experiments, 1.15 × 105 cells were seeded on 1% fibronectin coated Costar
Transwell®permeable filters (Ø = 6.5 mm; REF 3470; Corning Inc., Lowell, MA, USA). The medium
was changed every 2–3 days, and experiments were conducted after 7–10 days.
2.9. MTT Assay
Cytotoxicity of the nanocapsules was analyzed with a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as described previously [14]. Briefly, CFBE41o- and
16HBE14o- cells were seeded in a 96-well microtiter plate (1 × 104 cells per well) and incubated for
24 h at 37 ◦C, at 5% CO2 and 95% rH. Before application of the samples, the cells were washed twice
with serum-free cell culture medium. The cells were then incubated with the samples, under previous
conditions. After 24 h, the samples were removed and replaced by 100 µL serum-free cell culture
medium and 25 µL MTT solution (5 mg/mL in PBS), followed by another incubation of 4 h, to allow
formation of the purple formazan salt. The medium was removed, and the formazan was dissolved
with 100 µL dimethyl sulfoxide for 30 min, at 37 ◦C. Finally, the absorbance was measured at λ = 570 nm
in a microplate reader (EZ Read 400, Biochrom GmbH, Berlin, Germany), and relative viability was
calculated by dividing individual viabilities by the mean of the negative control (serum-free cell culture
medium). Then 1% Triton® X-100 was used as a positive control.
2.10. Transfection
Twenty-four hours before transfection, the medium of the CFBE41o- cells was replaced with
fresh antibiotic-free medium. CFBE41o- cells were transfected with 2.4 µg/cm2 wtCFTR-mRNA or
∆F508-CFTR-mRNA, respectively, using 1 µL of either blank or capsaicin-loaded nanocapsules per
Costar Transwell®permeable filter. Briefly, nanocapsules were mixed with the desired amount of
mRNA (0.3 µg/µL) and topped up with water, to a volume of 50 µL per filter. The formulations were
incubated at RT for 30 min to allow loading of the mRNA to the CS nanocapsules. After incubation,
the nanocapsules were mixed with Opti-MEM™ to reach a final volume of 100 µL per filter and
incubated for another 5 min at RT. Finally, the nanocapsules were added to the cells on the apical side
of the Costar Transwell®permeable filter, together with 200 µL of fresh cell culture medium, to reach
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a capsaicin concentration of 33 µM. Cells were incubated for 24 h at 37 ◦C, at 5% CO2 and 95% rH,
before experiments were conducted.
2.11. Transepithelial Measurements
Transepithelial short-circuit current (Isc) through monolayers cultured on Costar
Transwell®permeable filters was recorded with a transepithelial current clamp and a microcontroller
based data acquisition system (EP-Devices, Bertem, Belgium). Isc was calculated as ratio of open
circuit potential (PD) by transepithelial resistance (Rt). Rt was recorded from the voltage response
to a 1 Hz sine wave current stimulus. The data acquisition system was connected to an USB port
of a PC to display and store data. The instrument was built to simultaneously record Rt and PD
from four monolayers. The membrane area of the Costar Transwell®permeable filters is 0.33 cm2.
Four filters were mounted in four compartments in a Lucite holder. These compartments constituted
the basolateral bathing side and were filled with 1 mL of physiological medium. The volume of
solution at the apical side was 250 µL. Recording of Rt was done with a four electrode arrangement,
consisting of voltage sensing and current sending electrodes. Voltage and current electrodes were
Ag/AgCl pellets mounted in a holder, for connection to the data acquisition system. The four-channel
manifold could be accurately placed on the Lucite holder, and electrodes were positioned in the apical
and basolateral compartment. To add solutions, electrodes were moved to reference compartments in
the Lucite filter holder, where voltage electrode offsets were recorded. The Lucite holder was mounted
in a heating block with a temperature controller powered with 24 Volt DC supply. Temperature control
was set at 37 ◦C, and sensing was done with a Pt resistance probe inserted in the Lucite holder close to
the filter compartments. Basolateral bathing solutions were bubbled with air.
First, sodium current mediated by ENaC was evaluated. After adapting the cells to the
physiological Ringer solution (130 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 5 mM glucose,
and 10 mM HEPES; pH 7.3; 37 ◦C), sodium absorption through ENaC was blocked by apical application
of amiloride (10 µM; Sigma-Aldrich, St. Louis, MO, USA). To determine the overall sodium absorption
of the cells, sodium-free Ringer solution (130 mM tetramethylammonium chloride instead of NaCl)
was applied to the apical side afterward. To determine CFTR activity, ENaC was blocked again by
apical application of amiloride before an activation cocktail consisting of the membrane permeable
cAMP analogue 8-[4-chlorophenylthio (CTP)]-cAMP (100 µM; Biolog, Bremen, Germany) and IBMX
(1 mM; Sigma-Aldrich, St. Louis, MO, USA) was applied to the basolateral side of the monolayer.
The chloride current was blocked, using the specific CFTR channel blocker CFTRinh172 (10 µM in
amiloride solution; Tocris Cookson, Ellisville, MO, USA).
2.12. Statistical Analysis
GraphPad Prism® Version 6.01 (GraphPad Software Inc., La Jolla, CA, USA) was used for the
statistical analysis. If not stated otherwise, the arithmetic mean values ± standard deviations (SD) of at
least three independent experiments were determined. The data of the cell culture experiments are
expressed as the arithmetic mean values ± standard error of the mean (SEM). The non-parametric
Kruskal–Wallis test was performed to assess the significant differences of the data. Differences were
considered statistically significant when p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****).
3. Results
3.1. Physicochemical Characterization of Nanocapsules
The physicochemical properties of blank (NC Blank), as well as capsaicin-loaded (NC CAP)
nanocapsules, either naked or co-loaded with wtCFTR-mRNA at P/N charge ratio 75, were determined
with DLS-NIBS measurements and from their electrophoretic mobility. This specific P/N charge ratio
was chosen based on the transfection procedure as at P/N 75 the amount of wtCFTR-mRNA, as well
as capsaicin are ideal for transfection of CFBE41o- cells. The Z-average hydrodynamic diameter of
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the nanocapsules increased significantly after loading of capsaicin (Figure 1a). This outcome can
also be noticed in the intensity plot as the peak of the capsaicin-loaded nanocapsules shifts slightly
to the right. While the size of the nanocapsules increased, the polydispersity index (PDI) decreased
significantly for capsaicin-loaded nanocapsules (Figure 1b). In general, the nanocapsules appear to be
highly monodisperse as seen in the low PDI, as well as the narrow size distribution showing only one
monomodal population (Figure 1c). The increase in size runs in parallel with the nanocapsules’ zeta
potential, which also shows an increase after loading of capsaicin (Figure 1d). For all attributes, no effect
was noticeable after surface-loading the nanocapsules with wtCFTR-mRNA. The physicochemical
properties of the nanocapsules are summarized in Supplementary Materials Table S1.
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Figure 1. Physicochemical properties of chitosan (CS) nanocapsules. Shown is (a) the Z-average
hydrodynamic diameter, (b) polydispersity index (PDI), (c) relative intensity of scattered light,
and (d) zeta potential of blank (NC Blank) and capsaicin-loaded (NC CAP) nanocapsules either
naked or surface-loaded with wtCFTR-mRNA at P/N charge ratio 75 (p ≤ 0.05 (*); n = 3).
Blank and capsaicin-loaded nanocapsules were also successfully characterized by AF4, as shown
by an increasing hydrodynamic radius (Rh) with increasing elution time in the elugrams shown
in Figure 2. The gyration radius (Rg) also increased with advancing elution. Capsaicin-loaded
nanocapsules eluted slightly later than did blank nanocapsules, giving an indication of the greater
size of the loaded nanocapsules and confirmed by the DLS-NIBS online measurements. The shift in
elution is also observed in the comparison of the Rg/Rh ratios (shape factors) presented in Figure 2e.
Even though the ratios of both nanocapsules seem to be comparable, capsaicin-loaded nanocapsules
eluted later than blank nanocapsules. The size distribution parameters measured by AF4 are reported
in Table 2. As seen in Figure 2e, blank and loaded nanocapsules had similar shape factors, indicating
identical shapes of both.
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Table 2. Size distribution of CS nanocapsules determined by asymmetric flow field-flow fractionation.
Average gyration radii (Rg) determined by MALS, hydrodynamic radii (Rh) determined by DLS-NIBS
and shape factor (ρ = Rg/Rh) of blank (NC Blank) and capsaicin-loaded (NC CAP) nanocapsules (n = 3).
Nanocapsules Rg (nm) Rh (nm) ρ = Rg/Rh
NC Blank 72.70 ± 1.34 103.33 ± 3.12 0.70 ± 0.01
NC CAP 71.03 ± 0.05 102.50 ± 6.38 0.69 ± 0.05
For further analysis and visualization, TEM images were taken of blank and capsaicin-loaded
nanocapsules (Figure 3). The images show that capsaicin-loaded nanocapsules are larger than blank
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nanocapsules, confirming the DLS-NIBS and AF4 measurements. As seen in the images, the size
of blank nanocapsules varies between 100 and 150 nm, while capsaicin-loaded capsules show a
diameter of 200 to 250 nm, coinciding with DLS-NIBS measurements (137.5 ± 8.2 vs. 216.6 ± 35.3 nm).
The shape of the nanocapsules is also visible in the TEM images. As it seems, the nanocapsules are not
homogeneous or entirely spherical. On the contrary, some of the depicted nanocapsules appear to be
slightly elliptical.
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In order to test the effect of the nucleic acid loaded to the surface of the nanocapsules, their
physicochemical properties were characterized again. Capsaicin-loaded nanocapsules were co-loaded
with wtCFTR-mRNA, in a broad range of P/N charge r tios (5, 10, 50, 7 , and 100), followed by
DLS-NIBS and electrophoretic mobility measurements, as described previously. The nucleic acid
affected eit r t - r r i ia eter nor the PDI of the nanocapsules. As seen
in Figure 4a, the size of the anocapsules varied between 196 and 205 nm for all P/N cha ge ratios.
The PDI of the nanocap ul s remained at a very low level around ~0.1 (Figure 4b). Analysi of size
and PDI measurements were confirmed by the relative intensity of scattered light, i shifts
bet een the different P/N charge ratios (Figure 4c).
ile size and P I re ained stable, the zeta potential of the nanocapsules increased ith
increasi P/ charge ratio (+5 to + ; Fig re 4d). i ff t i i t t t t e additi of
lea s to odificatio of the nanocapsules’ electrophoretic obility, suggesting successful
surface-loading of the tCFTR- R A to the CS nanocapsules.
To verify the results of the zeta potential measurements arguing strongly in favor of the electrostatic
binding of the mRNA at the surface of the nanocapsules, a gel retardation assay was carried out
to investigate the binding efficiency of wtCFTR-mRNA and nanocapsules (Figure 5). The naked
wtCFTR-mRNA ran through the gel, forming a specific band around 4000 bases, corresponding to
its size (4563 bases), while both types of nanocapsules were retained in the gel pockets because of
their positive charge. No specific bands were visible in the lanes of the gene-loaded nanocapsules in
water or in transfection medium (Opti-MEM™), in good keeping with the zeta potential measurements
and suggesting the successful surface-loading of wtCFTR-mRNA onto the CS nanocapsules and high
stability in transfection medium. The original image of the gel retardation assay can be found in the
Supplementary Materials Figure S1.
Biomedicines 2020, 8, 364 10 of 21
Biomedicines 2020, 8, x FOR PEER REVIEW 10 of 22 
 
Figure 4. Physicochemical properties of CS nanocapsules surface-loaded with mRNA at varying P/N 
charge ratios. Shown is (a) the Z-average hydrodynamic diameter, (b) PDI, (c) relative intensity of 
scattered light, and (d) zeta potential of capsaicin-loaded nanocapsules surface-loaded with wtCFTR-
mRNA (n = 3). 
To verify the results of the zeta potential measurements arguing strongly in favor of the 
electrostatic binding of the mRNA at the surface of the nanocapsules, a gel retardation assay was 
carried out to investigate the binding efficiency of wtCFTR-mRNA and nanocapsules (Figure 5). The 
naked wtCFTR-mRNA ran through the gel, forming a specific band around 4000 bases, 
corresponding to its size (4563 bases), while both types of nanocapsules were retained in the gel 
pockets because of their positive charge. No specific bands were visible in the lanes of the gene-
loaded nanocapsules in water or in transfection medium (Opti-MEM™), in good keeping with the 
zeta potential measurements and suggesting the successful surface-loading of wtCFTR-mRNA onto 
the CS nanocapsules and high stability in transfection medium. The original image of the gel 
retardation assay can be found in the Supplementary Materials Figure S1. 
Figure 4. Physicochemical properties of CS nanocapsules surface-loaded with mRNA at varying P/N
charge ratios. Shown is (a) the Z-average hydrodynamic diameter, (b) PDI, (c) relative intensity
of scattered light, and (d) zeta potential of capsaicin-loaded nanocapsules surface-loaded with
wtCFTR-mRNA (n = 3).Biomedicines 2020, 8, x FOR PEER REVIEW 11 of 22 
 
Figure 5. Gel retardation assay of CS nanocapsules surface-loaded with mRNA. Shown is the result 
of a 1% agarose-formaldehyde gel electrophoresis of blank (NC Blank) and capsaicin-loaded (NC 
CAP) nanocapsules either naked or surface-loaded with wtCFTR-mRNA at P/N charge ratio 75 in 
water and in transfection medium (Opti-MEM™) after 24 h incubation at 37 °C. Naked wtCFTR-
mRNA showed a band at 4000 bases. Nanocapsules, both naked and surface-loaded, were retained in 
the pocket. Marker (M): RiboRuler™ High Range RNA Ladder (Thermo Fisher Scientific, Waltham, 
MA, USA). 
3.2. Stability of Nanocapsules 
The stability of the nanocapsules in transfection medium was examined before cell culture 
experiments were conducted. Capsaicin-loaded nanocapsules were incubated in Opti-MEM™ 
supplemented with HEPES and mannitol at 37 °C for 24 h, either naked or surface-loaded with 
wtCFTR-mRNA at P/N charge ratio 75. The size of the nanocapsules was determined by DLS-NIBS 
at different time points (0, 4, and 24 h). Both naked and surface-loaded nanocapsules remained 
extremely stable over time, as shown in Figure 6. The PDI of the nanocapsules stayed at low values 
between 0.07 and 0.09, and Z-average hydrodynamic diameter remained stable around 200 nm 
throughout 24 h, showing no shifts in the monomodal peaks of the intensity plots. 
Figure 5. Gel retard tion assay of CS nanocapsules surf l ith mRNA. Shown is th result of
a 1% agarose-formaldehyde gel electrophoresis of blank (NC Blank) and capsaicin-loaded (NC CAP)
nanocapsules either naked or surface-loaded with wtCFTR-mRNA at P/N charge ratio 75 in water and
in transfection medium (Opti-MEM™) after 24 h incubation at 37 ◦C. Naked wtCFTR-mRNA showed
a band at 4000 bases. Nanocapsules, both naked and surface-loaded, were retained in the pocket.
Marker (M): RiboRuler™ High Range RNA Ladder (Thermo Fisher Scientific, Waltham, MA, USA).
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3.2. Stability of Nanocapsules
The stability of the nanocapsules in transfection medium was examined before cell culture
experiments were conducted. Capsaicin-loaded nanocapsules were incubated in Opti-MEM™
supplemented with HEPES and mannitol at 37 ◦C for 24 h, either naked or surface-loaded with
wtCFTR-mRNA at P/N charge ratio 75. The size of the nanocapsules was determined by DLS-NIBS at
different time points (0, 4, and 24 h). Both naked and surface-loaded nanocapsules remained extremely
stable over time, as shown in Figure 6. The PDI of the nanocapsules stayed at low values between 0.07
and 0.09, and Z-average hydrodynamic diameter remained stable around 200 nm throughout 24 h,
showing no shifts in the monomodal peaks of the intensity plots.Biomedicines 2020, 8, x FOR PEER REVIEW 12 of 22 
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stability of capsaicin-loaded nanocapsules as (a) PDI and either (b) naked or (c) surface-loaded with
wtCFTR-mRNA at P/N charge ratio 75 as relative intensity of scattered light. Nanocapsules were
incubated in Opti-MEM™ supplemented with HEPES (20 mM) and mannitol (270 mM) at 37 ◦C.
Both naked and wtCFTR-mRNA-loaded nanocapsules remained stable over time (n = 3).
3.3. Cell Culture Experiments with Nanocapsules
The cytotoxicity of the nanocapsules was evaluated by an MTT assay (Figure 7). CFBE41o- cells
from a uman bronchial CF cell line, homozygous for the ∆F508 mut tion, were incubated with
blank nd capsaicin-loaded nanocapsules at varying concentrations, for 24 h, b fore the cell viabi ity
was asse sed. Neither blank nor capsaicin-loaded nanocapsules showed cytotoxic effects at low
concentrations of 0.33% corresponding to 33 µM of caps icin. Covering the capsules with mRNA
did not alter the effect. However, increasing concentrat o s of nanocapsules also increased their
cytotoxic effects, showing redu ed cell viability starting with nanocapsule concentrations of 1%.
While capsaicin-load nanocapsules onl dec eased the cell viability significa tly at concentrations of
5% (500 µM c psaicin; 40.9 ± 4.0%), blank n nocapsul s already showed significantly cytotoxic effects
at 2.5% (33.8 ± 2.8%). Blank nanocapsules at concentrations of 5% significantly decreased th cell
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viability to the level of the positive control (19.4 ± 1.9% vs. 21.9 ± 1.2%). The cell viability of the healthy
equivalent cell line 16HBE14o- was affected similarly, as shown in Supplementary Materials Figure S2.Biomedicines 2020, 8, x FOR PEER REVIEW 13 of 22 
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Figure 7. Effect of CS nanocapsules on the viability of CFBE41o- cells. Cells were incubated with blank
nanocapsules (NC Blank) and nanocapsules loaded with capsaicin (NC CAP), at varying concentrations
in Opti-MEM™, for 24 h, before an MTT assay was conducted. Concentrations correspond to 33, 100,
250, and 500 µM capsaicin in cells incubated with NC CAP. Cell culture medium was used as negative
control; Triton® X-100 was used as positive control. Significance was calculated compared to the
negative control (p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****); n = 3).
Based on the MTT assay, CFBE41o- cells were transfected with 2.4 µg/cm2 wtCFTR-mRNA or
∆F508-CFTR-mRNA using 0.33% nanocapsules. Then, 24 h after transfection, functional Ussing
chamber measurements were carried out in order to evaluate the effect of the transfection. As control,
the healthy equivalent bronchial epithelial cell line 16HBE14o- was used.
Transfection with wtCFTR-mRNA, using blank nanocapsules, did not lead to a change in potential
difference after application of cAMP, while the cAMP response was increased in cells transfected
with capsaicin-loaded nanocapsules (Figure 8a). Statistical evaluation of the short-circuit current (Isc)
showed that the increase in cAMP-mediated current was significant, indicating successful transfection
and CFTR expression (1.5 ± 0.3 µA/cm2 vs. 3.3 ± 0.6 µA/cm2; Figure 8b). As expected, transfection with
∆F508-CFTR-mRNA, using either blank or capsaicin-loaded nanocapsules, did not lead to a change in
cAMP response, corroborating the results achieved by transfection with wtCFTR-mRNA. Furthermore,
transepithelial measurements revealed significantly higher cAMP response in healthy control cells,
compared to the CF cell line CFBE41o-, indicating higher CFTR activity and thus validating the
expected behavior of the cells.
In order to estimate a possible effect of wtCFTR-mRNA transfection on ENaC, the amiloride-
sensitive current was evaluated (Figure 8c). After transfection using blank nanocapsules,
amiloride-sensitive current increased significantly. Treatment with capsaicin-loaded nanocapsules led to
a non-significant increase in amiloride-sensitive current. Transfection with ∆F508-CFTR-mRNA did not
alter the amiloride-sensitive current significantly, as compared to untreated CFBE41o- cells, even though
the cells treated with capsaicin-loaded nanocapsules displayed a slightly lower amiloride-sensitive
current. However, no difference in amiloride-sensitive current was observed between CFBE41o-
and healthy control cells 16HBE14o-, thus casting doubt on the validity of the cell lines regarding
ENaC activity.
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Figure 8. Transepithelial Ussing chamber measurements of epithelial cells before and after transfection
with mRNA. (a) Potential difference (PD) of representative time courses of non-transfected CFBE41o- cells
(control) and CFBE41o- cells transfected with wtCFTR-mRNA, using blank nanocapsules (NC Blank) and
capsaicin-loaded nanocapsules (NC CAP), respectively. (b) Statistical evaluation of cAMP-dependent
short-circuit current (Isc). Shown is the change of Isc after CFTR activation by application of cAMP.
(c) Statistical evaluation of amiloride-sensitive Isc. Shown is the percentage of sodium-current mediated
by ENaC. Cells were transfected with 2.4 µg/cm2 wtCFTR-mRNA or ∆F508-CFTR-mRNA, respectively.
Control cells were not transfected. Measurements were conducted 24 h after transfection (p ≤ 0.05 (*);
16HBE14o- n = 24; CFBE41o- n = 24; CFBE41o- + NC Blank (wtCFTR-mRNA) n = 20; CFBE41o- + NC
CAP (wtCFTR-mRNA) n = 28; CFBE41o- + NC Blank (∆F508-CFTR-mRNA) n = 24; CFBE41o- + NC
CAP (∆F508-CFTR-mRNA) n = 24).
4. Discussion
4.1. Highly Monodispers and Positively Charged Nanocapsul s Successfully Load wtCFTR-mRNA
In recent years, CS-based nanocapsules have been gaining traction for the delivery of drugs,
peptides, or antigens, to name a few [36–40]. This system was originally pioneered by the group of Prof.
Maria J. Alonso [41]. The optimization of the composition and preparation conditions were optimized [39],
and the role of the variation on the structural characteristics of chitosan (degree of acetylation and
molecular weight) on the physical characteristics, colloidal stability, and capsaicin-loading efficiency
were also subsequently studied [19,42].
Despite the many studies on CS nanocapsules as drug delivery systems, only very few have
reported about the delivery of genetic material [43,44]. Moreover, these nanosystems encapsulate the
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nucleic acids rather than loading them to their CS-covered surfaces, making the approach of this study
highly exceptional.
As CS-based nanocapsules are known for their increased stability and their interaction with
mucosal surfaces, making them interesting for transmucosal drug delivery [19,39,45], we aimed
at developing a similar system to improve transfection efficacy in the hostile milieu of the CF
lung. We obtained CS-covered nanocapsules either blank or loaded with the vanilloid capsaicin by
applying the spontaneous emulsification technique, which is also known as solvent displacement [20].
Features such as physical and chemical properties, as well as biological performance (e.g., transfection
efficiency) of CS, are dependent on molecular weight and degree of acetylation of the polysaccharide [46].
Therefore, it is crucial to rigorously characterize CS in order to design the most optimal formulation for
a specific purpose. To further optimize the suitability of CS-based nanocarriers as delivery systems, it is
essential to characterize them for their physicochemical properties and understand them on a molecular
level [15,47]. Thus, we characterized the nanocapsules regarding their physicochemical properties.
The Z-average hydrodynamic diameter increased around ~50 nm after loading the nanocapsules
with capsaicin revealed by DLS-NIBS measurements (Figure 1a). These results indicate successful
encapsulation of the vanilloid, as described before [19,22]. In fact, a previous study reported a strong
capsaicin-association efficiency (92%) in CS-lecithin oil-core nanocapsules [22], thus further validating
successful encapsulation. Measurements of the nanocapsules’ electrophoretic mobility also showed
increased zeta potential after encapsulation of capsaicin (Figure 1d). The increased positive charge
of the nanocapsules arises from the enlarged surface of the nanosystems exposing more positively
charged CS on the outside. In general, the nanocapsules displayed many auspicious attributes, such as
small size, low PDI, and high zeta potential (Supplementary Materials Table S1).
To further analyze the nanosystems in regard to their size and shape, they were characterized
upon fractionation by AF4 with multidetection. As the DLS-NIBS measurements already indicated,
the nanocapsules’ AF4 elution profiles revealed that the capsaicin-loaded nanocapsules are bigger
than their blank equivalent (Figure 2). Furthermore, the shape factor (Rg/Rh) was calculated from the
radii obtained from MALS and DLS-NIBS online measurements and, in this case, gives an indication
of the morphology of the nanocapsules. The shape factors for both blank and loaded nanocapsules
were around 0.69–0.70 (Table 2), a value which is lower than that expected for spheres (0.775).
These lower values are characteristic of core–shell structures, indicating that the mass concentrates in
the core region [48]. Furthermore, theoretical Rg/Rh ratio values for hard (0.775), homogeneous (0.778),
and hollow (1.0) spheres have been reported [49,50]. The lower Rg/Rh values found for the nanocapsules
in our study can be explained as a deviation from the standard spherical models. This hypothesis
was confirmed by TEM imaging that revealed few spherical shapes but also partially elliptical and
vesicle-shaped smaller structures (Figure 3).
After general characterization of the nanocapsules, they were further investigated regarding their
physicochemical properties when surface-loaded with wtCFTR-mRNA at varying P/N charge ratios
(5, 10, 50, 75, and 100). The Z-average hydrodynamic diameter, as well as the PDI of the nanocapsules,
remained stable (Figure 4a–c). This might be explained by the fact that we only used very low amounts
of mRNA, which are not enough to result in an increase of thickness of the shell. In contrast, the zeta
potential of the nanocapsules increased with increasing P/N charge ratio (Figure 4d). This expected
increase demonstrates successful loading of the nucleic acid to the surface of the nanocapsules.
With increasing P/N charge ratio, less mRNA is applied to the nanocapsules, and, therefore, fewer
negatively charged phosphate groups can take part in the neutralization of the positively charged
amine groups of the CS leading to an increase in zeta potential. This phenomenon was described before,
in this study and by others [13,51–53], validating the result of zeta potential measurements. The gel
retardation assay shown in Figure 5 further enforces the successful surface-loading of wtCFTR-mRNA
to the nanocapsules, as the nucleic acid was completely retained in the gel pocket by the CS-covered
nanosystems. The outcome of the gel retardation assay corroborates previous reports showing overall
strong binding efficiency of nucleic acids and CS [13,14,54,55].
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The small size below 500 nm, low PDI, and highly positive zeta potential increase their chance of
endocytotic uptake because of their interaction with the negatively charged cell membrane [56,57].
These attributes, as well as the successful loading of wtCFTR-mRNA to the surface of the CS-covered
nanocapsules, make the system very promising for transfection purposes.
4.2. Nanocapsules are Highly Stable in Transfection Medium
Aggregation of nanosystems can significantly alter their fate, such as uptake by cells, as well
as their cytotoxicity or biodistribution, to name a few [58]. Therefore, it is indispensable to evaluate
their colloidal stability in a cell culture environment in order to guarantee successful transfection and
effective translation into clinical applications. Hence, the stability of the nanocapsules in transfection
medium was evaluated before cell culture experiments were performed. Naked and surface-loaded
nanocapsules were incubated in Opti-MEM™ supplemented with HEPES and mannitol for 24 h
at 37 ◦C. The supplements were chosen based on a recommendation for a CS-based transfection
reagent from NovaMatrix® (Sandvika, Norway). The idea behind supplementation of the transfection
medium is the stabilization of the nanosystems with short-range repulsive hydration forces, which are
produced by accumulation of the reagents close to their hydrophilic surface [13]. Both systems
remained stable over time (Figure 6), as reported by previous studies [22,59]. However, the transfection
medium supplemented with HEPES and mannitol was reported to display a very high osmolality,
around 580 mOsmol/kg, having a shrinking effect on the cells [14]. Based on these data, transfection
experiments should be conducted in medium without supplements. Previous studies showed that
CS-lecithin oil-core nanocapsules also remained stable in unsupplemented medium, which can be
applied to our systems, as well [22,59]. Therefore, transfection experiments were performed, using
unsupplemented Opti-MEM™.
4.3. wtCFTR-mRNA Transfection Using Capsaicin-Loaded Nanocapsules Restores CFTR Function
The concept of mRNA delivery to cells for therapeutic purposes, referred to as transcript therapy,
has been on the rise in the last years [2,3,10]. The use of mRNA instead of DNA, like in the classical
definition of gene therapy, displays many advantages, such as higher translation efficacy, decreased
immunogenicity, and increased overall safety, as mRNA is not incorporated into the genome, to name
a few [60]. Because CF is a single-gene based disease, this model of treatment is highly promising for a
potential gene therapy, as shown by an ongoing clinical trial testing the delivery of wtCFTR-mRNA
via inhalation of lipid nanoparticles [3].
We have been using wtCFTR-mRNA to transfect CF airway epithelial cells to correct CFTR function
and subsequently abnormal chloride secretion constantly optimizing the transfection procedure [10,12].
In this study, the CF cell line CFBE41o- was transfected with wtCFTR-mRNA, using blank and
capsaicin-loaded CS-lecithin oil-core nanocapsules. Functional Ussing chamber measurements were
conducted 24 h after transfection and revealed significantly increased cAMP-dependent short-circuit
current to the levels of healthy control cells in cells transfected with the capsaicin-loaded nanocapsules
(Figure 8b). Furthermore, cells were transfected with ∆F508-CFTR-mRNA as negative control, followed
by Ussing chamber measurements revealing no change in cAMP response (Figure 8b). These results
indicate successful wtCFTR-mRNA transfection and, hence, increased CFTR function.
Approximately 5% of normal wtCFTR-mRNA level is sufficient to avoid the severe complications
of CF [61]. For a sufficient chloride secretion, the airway epithelium requires about 6–10% epithelial
cells expressing functional CFTR [62]. Mucociliary clearance is guaranteed with 25% epithelial cells
expressing the chloride channel [63]. In a previous study, we were able to determine a transfection
efficiency over 50%, using CS in the same cell line [13]. Therefore, and because of the restored
cAMP-dependent short-circuit current shown with the Ussing chamber measurements, it can be
assumed that in this study enough cells were transfected and hence express functional CFTR for
sufficient chloride efflux and further regulatory functions.
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The delivery of chemically modified wtCFTR-mRNA using nanomedicine in vivo was recently
reported demonstrating the relevance of nanotechnology in CF research. Haque et al. used CS-coated
poly-(lactic-co-glycolic acid) nanoparticles assembled with CFTR-mRNA for intratracheal spraying and
intravenous injection in CFTR deficient (CFTRtm1Unc) mice. They reported significantly improved lung
function in the tested rodents [64]. Robinson et al. were able to restore CFTR-mediated chloride secretion
for at least two weeks and recovered around 55% of the net chloride efflux in the same mouse line.
To achieve this outcome, they used lipid-based nanoparticles for nasal application [65]. These studies
corroborate the results of the Ussing chamber experiments in this study, which also demonstrated
increased CFTR function after wtCFTR-mRNA delivery, using nanoparticles. However, the murine
model of CF often fails to reflect human pulmonary pathology [66,67]. Therefore, the pertinence of
these studies should be regarded cautiously.
In contrast to the results achieved with capsaicin-loaded nanocapsules, cells transfected with the
blank nanocapsules did not show any change in cAMP-dependent short-circuit current. The difference
in transfection efficiency might be explained by the ability of capsaicin to reversibly open tight
junctions [21], increasing the probability of the loaded nanocapsules to enter the cells. Furthermore,
the MTT test revealed that blank nanocapsules displayed a higher cytotoxicity than the capsaicin-loaded
nanocapsules (Figure 7), proposing that capsaicin might have a beneficial effect on nasal epithelial cells.
Similar results were reported in a study of Kaiser and colleagues. They described significantly decreased
cell viability of canine kidney epithelial cells (MDCK-C7) when incubated with blank nanocapsules,
while capsaicin-loaded nanocapsules did not alter the viability of the cells [22]. The increased cytotoxicity
might be the reason for the reduced transfection efficiency of blank nanocapsules.
In CF, the loss of CFTR function not only leads to decreased chloride secretion, but also to sodium
hyperabsorption through the negatively regulated ENaC further thickening the mucus resulting in the
classical clinical picture [68]. Therefore, the amiloride-sensitive current of CFBE41o- cells transfected
with wtCFTR-mRNA was also assessed in this study, as amiloride is a specific blocker of ENaC.
In contrast to the expectations, amiloride-sensitive current of cells was increased after wtCFTR-mRNA
transfection, using nanocapsules (Figure 8c). CS has been reported to have various effects on proteins
of the cell. For example, CS is able to translocate tight junction proteins from the cell membrane to the
cytoskeleton [69]. Furthermore, it was shown that, after incubation with CS-sodium tripolyphosphate
particles, liver cells upregulated eight proteins (Amyloid beta A4 protein, C-C chemokine receptor
type 8, CD44 antigen, G2/mitotic-specific cyclin-B2, Neuroblast differentiation-associated protein,
Osteonectin/SPARC protein, Glutamate receptor ionotropic, kainite 5, and Rho GTPase-activating
protein 6) associated with regulative functions, such as differentiation, cell cycle regulation, or cell
division [70]. Considering this, an effect of CS on ENaC might be the reason for the increased
amiloride-sensitive current after application of the CS nanocapsules.
While the increase of amiloride-sensitive current was only minor in cells transfected with
capsaicin-loaded nanocapsules, the increase after transfection with blank nanocapsules was significant.
The observed difference in amiloride-sensitive current, albeit small, might be explained by the activation
of TRPV1 through capsaicin in cells treated with the capsaicin-loaded nanocapsules. This theory is
further corroborated by the results achieved after transfection with ∆F508-CFTR-mRNA. Even though
no significant difference in amiloride-sensitive current could be observed compared to untreated
control cells, the amiloride-sensitive current in cells treated with the capsaicin-loaded nanocapsules
was slightly lower than in cells treated with the blank nanocapsules or the untreated cells (Figure 8c).
While the activation of TRPV1 through its agonist capsaicin usually leads to acute and persistent
pain [71,72], a study of Li and colleagues reported reduced α-ENaC expression and ENaC activity in
the kidney of mice after TRPV1 activation via capsaicin [31]. According to them, ENaC activity is
inhibited indirectly through protein kinase C, which is activated by TRPV1 [31], a theory, which is
supported by another report showing inhibited ENaC currents in the lungs of rats after activation of
protein kinase C [73].
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However, the mice in the study of Li and colleagues were exposed to the vanilloid for 10 months,
through a capsaicin diet, before the experiments were conducted [31]. Another study showing positive
effects of capsaicin on nasal epithelial cells conducing in vivo studies with patients suffering from
idiopathic rhinitis applying capsaicin to the nasal mucosa reported those effects after 12 weeks of
treatment [74]. Therefore, 24 h of incubation with capsaicin-loaded nanocapsules, as conducted in the
present study, might not be enough to evoke the full effect of the vanilloid.
The cell lines used in this study might be a good model for the investigation of chloride secretion;
however, they do not represent the classical picture of CF regarding sodium hyperabsorption. CFBE41o-
cells have been reported to display reduced ENaC expression and amiloride-sensitive current [75,76],
as does the healthy equivalent cell line 16HBE14o- [77]. The dubiety of the two cells lines regarding
ENaC activity was confirmed with functional Ussing chamber experiments, as both healthy and CF cell
lines displayed the same amount of amiloride-sensitive current (Figure 8c). An adequate evaluation of
the presented data regarding ENaC activity is, hence, not feasible. Therefore, transcript therapy alone
might be sufficient to restore the imbalanced ion transports in CF in vivo.
5. Conclusions
In this study, we successfully developed natural, non-toxic, and non-viral nanocarriers for the
delivery of mRNA to target cells. The nanocapsules, based on the natural aminopolysaccharide
chitosan, displayed promising characteristics for transfection experiments, such as small size, high
stability in transfection medium, and low cytotoxicity. We showed successful incorporation of capsaicin
into the nanocapsules, as well as surface-loading of wtCFTR-mRNA, further increasing their suitability
for transfection purposes. Finally, transepithelial measurements in a new state-of-the-art Ussing
chamber demonstrated effectively restored CFTR function in the cystic fibrosis cell line CFBE41o- after
transfection with wtCFTR-mRNA, using nanocapsules loaded with capsaicin. The results presented in
this study reinforce the promising opportunities of nanobiotechnology not only for a possible cystic
fibrosis transcript therapy, but for non-viral gene delivery in general.
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